Blog · Weight Loss
If your progress on semaglutide has slowed, or you have read that tirzepatide led to more weight loss in a head-to-head trial, you may be thinking about switching from semaglutide to tirzepatide. This guide covers what the U.S. labels and the published research actually say, what they leave open, and how Dr. Melanie Espinet handles a switch at MeliOra Elite Wellness in Lutz. For a side-by-side look at the two medicines themselves, see our semaglutide vs. tirzepatide comparison.
Semaglutide acts on one gut hormone pathway, GLP-1. Tirzepatide acts on two, GLP-1 and GIP. In the SURMOUNT-5 trial, which compared them directly in adults with obesity but without type 2 diabetes, average weight loss after 72 weeks was about 20 percent of body weight on tirzepatide and about 14 percent on semaglutide. That gap in the averages is the main reason people ask about a switch. The usual situations look like this:
A plateau is not automatically a reason to switch. Weight loss naturally slows over time, and sometimes the better answer is a dose change, more protein, or simply more time. Our guide to a semaglutide plateau walks through what to check first. If semaglutide is still working and you tolerate it well, there may be no reason to change at all.
No. There is no official dose conversion between semaglutide and tirzepatide. The U.S. label for Wegovy, a semaglutide brand, gives switching steps only between its own injection and tablet forms. The label for Zepbound, a tirzepatide brand, gives no steps for coming from semaglutide. Each label starts at its own lowest dose and climbs from there.
The milligram numbers also sit on different scales. These are different molecules that act on different sets of hormone receptors, so a 2.4 mg dose of one and a 5 mg dose of the other are not more or less of the same thing. Charts that pair doses side by side, including ones you may find online, do not come from either label. Treat them as someone’s estimate, not a rule.
| Label detail | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|
| Starting dose | 0.25 mg once a week | 2.5 mg once a week, a dose meant only for getting started |
| How the dose rises | A step up every 4 weeks, reaching 1.7 mg at week 13 | 2.5 mg steps, at least 4 weeks apart |
| Maintenance dose for weight | 1.7 mg or 2.4 mg a week, with up to 7.2 mg for some adults | 5, 10, or 15 mg a week |
| Half-life | About 1 week | About 5 days |
| Use with another GLP-1 medicine | Not recommended on either label. | |
| Steps for switching between the two | None on either label. | |
These are label facts for the brand-name products, shown so you can see why the numbers do not convert. Dr. Espinet prescribes semaglutide or tirzepatide and explains your own medication and dose at your visit.
Because no chart applies, the plan is built around you. Guidance from the American College of Physicians says that when a patient switches weight medicines because the first one is not working well enough, the patient and clinician should talk through benefits, harms, cost, access, other health conditions, weight goals, and preferences. In practice, Dr. Espinet looks at four things before she sets a date or a dose:
Timing matters because semaglutide lingers. Its label says that after a final 2.4 mg dose, semaglutide stays in the blood for about 5 to 7 weeks. So your first tirzepatide dose meets some semaglutide that is still on board. Neither label sets a waiting period for this, which is one more reason the timing is a physician’s decision and not a calendar rule.
The starting dose is the other big question. The Zepbound label starts everyone at 2.5 mg. One published study took a different path: adults with type 2 diabetes who were stable on a GLP-1, most often semaglutide or dulaglutide, moved straight to tirzepatide 5 mg. Over 12 weeks, their blood sugar improved a little and their weight dropped by about 2 kilograms (under 5 pounds) on average, and about 13 percent had stomach side effects. That study was short, limited to people with diabetes, and several of its authors worked for Eli Lilly, which makes tirzepatide. It does not set a rule for weight loss patients. It does show why a physician may start some people at the first step and others a step higher.
Plan for a start-up period that may feel familiar. Tirzepatide’s dose rises in steps, and in the head-to-head trial, stomach side effects with both medicines were most common while the dose was going up. Most were mild to moderate. Tell your physician early so the pace can be slowed if needed. Our guide to tirzepatide side effects covers what to watch for and when to call.
How much more weight you might lose is less certain than the head-to-head trial suggests, because that trial started people fresh rather than switching them. The best real-world look we found is a chart review from Weill Cornell Medicine published in 2026. It followed 61 adults who moved from semaglutide at 1.7 mg a week or more to tirzepatide after a plateau or a weak response. After six months on tirzepatide, they had lost about 5 percent more of their body weight on average. People who switched at a plateau, after losing at least 5 percent on semaglutide, lost about 8 percent more. People who had lost less than 5 percent on semaglutide lost about 3 percent more.
If you take birth control pills, plan ahead. The Zepbound label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. That applies when you come from semaglutide too.
Yes, a switch can go the other way too. People ask about it because of cost, side effects, or a change in goals. At MeliOra, semaglutide is $150/month at starting doses and $240/month for higher dosing, while tirzepatide is $230/month at starting doses and $320/month for higher dosing.
The same rules apply in this direction: no conversion chart, never both at once, and a starting dose your physician chooses. We found little published data on switching from tirzepatide to semaglutide, so the decision rests mostly on your own history. If you are moving to semaglutide to save money, talk about how the lower average weight loss in trials might affect your goals, and keep regular check-ins so any regain is caught early. If you are thinking about stopping altogether instead, read what happens when you stop semaglutide first.
Many people who ask about switching are already on a GLP-1 from an online program or another clinic. You can move your care to MeliOra and change medicines at the same time if that makes sense, or keep the same medicine with a new physician. Bring the name of your medication, your current dose, the date of your last injection, and the pharmacy that fills it. Do not stop early or take extra doses while you wait for your visit. Our comparison of concierge and online GLP-1 care explains what changes when one physician follows you.
The same approach applies to other GLP-1 switches, such as moving from daily liraglutide to a weekly shot. See liraglutide vs. semaglutide for how those two compare.
Dr. Melanie Espinet, a board-certified family physician, handles every switch herself. Your visit can be a house call anywhere in our Tampa Bay service area with no travel fee, an appointment at the Lutz office, or a secure video visit through GLP-1 telehealth if you are in Florida. She reviews your history and lab work, sets your timing and starting dose, and follows up as your dose rises. If semaglutide is still serving you well, she will tell you that too.
There is no consultation fee for GLP-1 care. Tirzepatide is $230/month at starting doses and $320/month for higher dosing, compared with $150/month and $240/month for semaglutide, and your monthly price follows the dose Dr. Espinet prescribes. Both prices include physician visits, lab work, medication and supplies, dose adjustments, and check-ins. See tirzepatide in Lutz and Tampa for the full program, or book a consultation to talk through your options.
There is no official waiting period, so your physician sets the timing. Neither U.S. label gives steps for moving between the two medicines. Semaglutide stays in the blood for weeks after the last dose, which is one reason the timing is decided case by case.
Not always, but 2.5 mg is the label’s starting dose. Because there is no conversion between the two medicines, your physician decides whether you start there or a step higher, based on your semaglutide dose, how long you took it, and how you tolerated it.
No, there is no official dose conversion. The two are different molecules on different milligram scales, and neither U.S. label gives a conversion. Charts that pair doses are estimates, not label guidance.
No. Both U.S. labels say using them with another GLP-1 medicine is not recommended. Start the new medicine only when your physician tells you to.
It may, especially if semaglutide worked well before it stalled. In a 2026 real-world study, people who switched after a plateau lost about 8 percent more body weight over six months, while people who had lost less than 5 percent on semaglutide lost about 3 percent more. Results vary from person to person.
They may, especially in the first weeks and after each dose increase. In the head-to-head trial, stomach side effects with both medicines were most common while the dose was going up, and most were mild to moderate. Tell your physician early so the pace can be slowed.
Usually, yes. Tirzepatide is $230/month at starting doses and $320/month for higher dosing, compared with $150/month and $240/month for semaglutide, and your price follows the dose Dr. Espinet prescribes. Both monthly prices include physician visits, lab work, medication and supplies, dose adjustments, and check-ins.
Serving Lutz, Wesley Chapel, Land O'Lakes, Carrollwood, New Tampa & greater Tampa Bay.
Book Your Consultation
Free download · 15 pages
Typical units and cost by area, Botox brands Jeuveau vs. Xeomin, aftercare, a results timeline and a planner you can fill in. Free, and yours to keep.
Get the free guide
